CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jul. 30, 2017	Jul. 31, 2016
Cash flows from operating activities:
Net income	$ 37,234	$ 32,026
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	30,656	32,107
Amortization of deferred financing costs	1,398	1,431
Share-based compensation expense	8,146	7,711
Gain on insurance recovery	(9,749)	0
Loss (gains) on assets, net	438	(3,568)
Provision for doubtful accounts	1,145	1,515
Provision for deferred income taxes	70	1,573
Excess tax (benefits) from share-based compensation arrangements	(1,515)	(867)
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(8,559)	(10,102)
Inventories	(25,909)	(25,309)
Income taxes	(1,284)	0
Prepaid expenses and other	1,069	1,150
Accounts payable	(22,212)	499
Accrued expenses	(10,499)	2,550
Other, net	(1,347)	(117)
Net cash (used in) provided by operating activities	(918)	40,599
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	(4,343)
Capital expenditures	(15,629)	(15,140)
Proceeds from sale of property, plant and equipment	2,533	5,479
Proceeds from insurance	8,593	0
Net cash used in investing activities	(4,503)	(14,004)
Cash flows from financing activities:
Refund (deposit) of restricted cash	96	(44)
Proceeds from stock options exercised	1,195	12,055
Excess tax benefits from share-based compensation arrangements	1,515	867
Proceeds from Amended ABL facility	35,000	0
Payments on Amended ABL facility	(35,000)	0
Payments on term loan	(10,180)	(30,000)
Payments on note payable	(1,096)	(974)
Purchases of treasury stock	(5,922)	(57,401)
Net cash used in financing activities	(14,392)	(75,497)
Effect of exchange rate changes on cash and cash equivalents	333	(50)
Net decrease in cash and cash equivalents	(19,480)	(48,952)
Cash and cash equivalents at beginning of period	65,403	99,662
Cash and cash equivalents at end of period	$ 45,923	$ 50,710